Filtered By:
Specialty: Cardiology
Drug: Plavix
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 545 results found since Jan 2013.
P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial
CONCLUSIONS: P2Y₁₂ inhibitor monotherapy, mostly clopidogrel, following 3 months of DAPT did not increase ischemic events in patients with complex PCIs.PMID:34523115 | DOI:10.5603/CJ.a2021.0101
Source: Cardiology Journal - September 15, 2021 Category: Cardiology Authors: Ji Woong Roh Joo-Yong Hahn Ju-Hyeon Oh Woo Jung Chun Yong Hwan Park Woo Jin Jang Eul-Soon Im Jin-Ok Jeong Byung Ryul Cho Seok Kyu Oh Kyeong Ho Yun Deok-Kyu Cho Jong-Young Lee Young-Youp Koh Jang-Whan Bae Jae Woong Choi Wang Soo Lee Hyuck Jun Yoon Seung Uk Source Type: research
Antithrombotic therapy in high-risk patients after percutaneous coronary intervention; study design, cohort profile and incidence of adverse events
CONCLUSION: The high risk for both bleeding and ischaemic events in this cohort of patients with multiple clinical risk factors illustrates the challenges that the cardiologist faces to make a balanced decision on the optimal treatment strategy. This cohort will serve to answer several future research questions about the optimal management of these patients on dual/triple antithrombotic therapy, and the possible value of a wide range of laboratory tests to guide these decisions.PMID:34468944 | DOI:10.1007/s12471-021-01606-2
Source: Netherlands Heart Journal - September 1, 2021 Category: Cardiology Authors: R H Olie P E J van der Meijden M J A Vries L Veenstra A W J van 't Hof J M Ten Berg Y M C Henskens H Ten Cate Source Type: research
A Clinical Update on Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke
AbstractPurpose of ReviewAntiplatelet therapy remains the standard of care in secondary stroke prevention for non-cardioembolic ischemic stroke and transient ischemic attack. We aim to examine the use of antiplatelet agents in secondary prevention through highlighting relevant clinical trials and meta-analyses as well as providing commentary regarding our practice.Recent FindingsIn the POINT and CHANCE trials, dual antiplatelet therapy reduced recurrent stroke compared to aspirin monotherapy. Sub-analyses of these trials suggest that genetic polymorphisms could play a role in diminishing the effectiveness of clopidogrel. S...
Source: Current Cardiology Reports - August 19, 2021 Category: Cardiology Source Type: research
Efficacy and safety of ticagrelor versus clopidogrel with different dosages in acute coronary syndrome patients with high GRACE and CRUSADE scores
CONCLUSIONS: In PCI patients with a high ischemic and bleeding risk, the ticagrelor antiplatelet strategy significantly reduced the MACCE rate without increasing the risk of major bleeding. A decreased MACCE rate was also observed in patients administered the double dosage of clopidogrel, but the bleeding risk was increased compared with the control group.PMID:34154742 | DOI:10.1016/j.ihj.2021.02.002
Source: Indian Heart J - June 22, 2021 Category: Cardiology Authors: Peng Xiao Feng Xie Yunjing Lan Source Type: research
